NR1H3 and glioblastoma: demonstrated that YTHDF2 affects the survival of GBM patients by promoting m6A-dependent mRNA decay of LXRα and HIVEP2, and that YTHDF2 promotes tumorigenesis of GBM by downregulating LXRα and HIVEP2 (146).